We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of ITGAM in Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01230112
First Posted: October 28, 2010
Last Update Posted: July 30, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Northwell Health
  Purpose
Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Condition
Systemic Lupus Erythematosus

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by Northwell Health:

Biospecimen Retention:   Samples With DNA
Blood and DNA will be collected and retained

Enrollment: 40
Study Start Date: December 2009
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Normal Control Subjects with genotype of interest registered in the Genotype and Phenotype Registry
Criteria

Inclusion Criteria:

  • males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
  • Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria:

  • History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
  • History of cancer or lymphoma
  • Current use of aspirin, prednisone, or NSAID or any immunosuppressant
  • Self reported HIV
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230112


Locations
United States, New York
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Sponsors and Collaborators
Northwell Health
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Responsible Party: Northwell Health
ClinicalTrials.gov Identifier: NCT01230112     History of Changes
Other Study ID Numbers: 09-289
First Submitted: October 27, 2010
First Posted: October 28, 2010
Last Update Posted: July 30, 2013
Last Verified: July 2013

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases